UBS analyst Eliana Merle lowered the price target on Moderna (NASDAQ: MRNA) to $40.00 (from $70.00) while maintaining a Buy ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE